← FDA DRUG APPROVALS

FDA ANDA · ANDA202485

GEMCITABINE

gemcitabine hydrochloride

Sponsor: JIANGSU HANSOH PHARM

APPLICATION
ANDA202485
TYPE
ANDA
ORIGINAL APPROVAL
2013-05-07
LATEST ACTION
2024-09-24
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

GEMCITABINE HYDROCHLORIDEPrescription
GEMCITABINE HYDROCHLORIDE EQ 1GM BASE/VIAL · INJECTABLE · INJECTION
GEMCITABINE HYDROCHLORIDEPrescription
GEMCITABINE HYDROCHLORIDE EQ 200MG BASE/VIAL · INJECTABLE · INJECTION

Approval history

2024-09-24Labeling · Supplement 18 · standardAP
2019-10-03Labeling · Supplement 5 · standardAP
2019-10-03Labeling · Supplement 8 · standardAP
2019-10-03Labeling · Supplement 4 · standardAP
2019-10-03Labeling · Supplement 9 · standardAP
2013-05-07UNKNOWN · OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →